EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 232 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Majority of Patients With Cancer Are Willing To Be Vaccinated Against... February 2, 2021 Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... October 9, 2024 Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer March 15, 2022 FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer May 8, 2024 Load more HOT NEWS Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer... Reunión anual de la American Society of Clinical Oncology de 2023:... Artist Tattoos Realistic Nipples On Breast Cancer Survivors Post-Mastectomy
